InflaRx (NASDAQ:IFRX) Short Interest Up 36.8% in March

InflaRx (NASDAQ:IFRX) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totalling 794,600 shares, a growth of 36.8% from the March 15th total of 581,000 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average trading volume of 391,800 shares, the short-interest ratio is currently 2.0 days.

InflaRx Price Performance

Shares of NASDAQ:IFRX opened at $1.06 on Friday. The stock has a market cap of $71.16 million, a price-to-earnings ratio of -0.98 and a beta of 2.21. InflaRx has a 12 month low of $0.82 and a 12 month high of $2.82. The stock’s 50 day moving average price is $1.32 and its 200 day moving average price is $1.83.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. On average, sell-side analysts expect that InflaRx will post -1.04 EPS for the current year.

Hedge Funds Weigh In On InflaRx

Several large investors have recently made changes to their positions in IFRX. Northern Trust Corp raised its holdings in shares of InflaRx by 1,933.1% in the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company’s stock worth $1,647,000 after purchasing an additional 634,045 shares in the last quarter. Raymond James Financial Inc. acquired a new position in InflaRx in the fourth quarter worth approximately $1,576,000. Commonwealth Equity Services LLC increased its holdings in shares of InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock valued at $275,000 after buying an additional 19,000 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of InflaRx by 32.8% during the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of InflaRx during the 4th quarter worth $55,000. Institutional investors own 42.39% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Guggenheim boosted their price target on InflaRx from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a report on Friday, March 21st.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.